You are here: Industry Insights > Roche

News List

With latest data, has Roche's Tecentriq found a blockbuster lung cancer niche? fiercepharma
June 26, 2018
So far, Roche’s Tecentriq hasn’t been able to find a piece of the lung cancer market to call its own. But that may change after its latest trial win.
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study fiercevaccines
June 26, 2018
Roche’s multiple sclerosis newcomer Ocrevus was approved by the FDA last March bearing a warning about immunization.
Roche buys out rest of Foundation Medicine for $2.4bn pharmafile
June 22, 2018
Roche has clearly seen significant potential in Foundation Medicine’s work in genomics to pay $2.4 billion to take complete ownership of the company.
Roche snaps up rest of Foundation Medicine for $2.4bn pharmatimes
June 21, 2018
Roche is buying the shares it does not already own in US molecular information company Foundation Medicine (FMI), in a deal valued at $2.4 billion.
New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan worldpharmanews
June 20, 2018
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL)
TESARO, Roche to evaluate triplet therapy for ovarian cancer biospectrumasia
June 07, 2018
TESARO and Genentech are also working together to evaluate the combination of ZEJULA and atezolizumab in patients with metastatic bladder cancer as a part of MORPHEUS, Roche's novel cancer immunotherapy development platform.
Roche's breast, lung cancer offerings fail to impress at ASCO pharmafile
June 07, 2018
Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data which demonstrated only mediocre efficacy for two of its therapies for breast and lung cancer.
Roche resigns itself to failure on SMA drug pharmafile
June 07, 2018
Roche has announced that it will no longer seek to develop its treatment for spinal muscular atrophy (SMA), olesoxime, after encountering too many difficulties in bringing it through to patients.
Roche's multiple sclerosis drug Ocrevus lowered patients' vaccine responses: study fiercepharma
June 07, 2018
Roche’s multiple sclerosis newcomer Ocrevus was approved by the FDA last March bearing a warning about immunization.
How different are I-O stars from Merck, Roche and Bristol-Myers? Depends who you ask fiercepharma
June 07, 2018
It’s no secret that most ASCO watchers decided Merck's data on immuno-oncology star Keytruda would cement its position as king of the all-important lung cancer market.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page